Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Plos One|March 13, 2020
Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy dataGiuseppe Roberto, Andrea Spini, Claudia Bartolini, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Characteristics of Primary Cutaneous Lymphoma in Italy: A Tertiary Care, Single-Center StudyMartina D'Onghia, Alessandra Cartocci, Laura Calabrese, et al.
Frontiers in Oncology|June 16, 2023
Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indicationsClaudia Bartolini, Giuseppe Roberto, Anna Girardi, et al.
European Journal of Haematology|January 20, 2022
Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma network)Emanuele Cencini, Bianca Mecacci, Melania Rocco, et al.
Leukemia Research|June 18, 2014
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemiaAlessandro Gozzetti, Veronica Candi, Alberto Fabbri, et al.
Cancers|January 20, 2021
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell TherapyMiriam Marangon, Carlo Visco, Anna Maria Barbui, et al.
Cancer Drug Resistance (Alhambra, Calif.)|June 5, 2024
Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patientsGabriele Perrone, Luigi Rigacci, Giandomenico Roviello, et al.
Leukemia & Lymphoma|January 21, 2025
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network)Emanuele Cencini, Marianna Palazzo, Dimitri Dardanis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter studyDaniele Laszlo, Giovanna Andreola, Luigi Rigacci, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life ExperienceMarina Moretti, Anna Marina Liberati, Luigi Rigacci, et al.
Pageof 9